Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
An Open Label Extension, Investigator Initiated Trial to Examine Radiographic Progression , Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis. EASIC (European Ankylosing Spondylitis Infliximab Cohort)
Sponsor: Centocor BV
Listed as NCT00237419, this NA trial focuses on Ankylosing Spondylitis and remains ongoing. Sponsored by Centocor BV, it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Jun 2025 — Sep 2025 [monthly]
Unknown NA
-
Oct 2024 — Jun 2025 [monthly]
Unknown NA
-
Sep 2024 — Oct 2024 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
▶ Show 3 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status NA
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status NA
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centocor BV
- PPD Development, LP
- Rheumazentrum Ruhrgebiet
- Trial Coordination Center, 9713 GZ Groningen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Berlin, Germany , Brussels, Belgium , Cambridge, United Kingdom , Diepenbeek, Belgium , Ghent, Belgium , Helsinki, Finland , Herne, Germany , Leeds, United Kingdom , Leuven, Belgium and 3 more locations